Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pharmacokinetics of Midazolam Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

NCT01069822
View directory record Official record
Conditions
Healthy
Interventions
AZD6765, midazolam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Jul 23, 2026, 4:10 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)

NCT07435194
View directory record Official record
Conditions
Healthy
Interventions
MK-2828, Itraconazole, Midazolam
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
24 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Midazolam in Healthy Adults

NCT04679623
View directory record Official record
Conditions
Status Epilepticus
Interventions
Midazolam, Seizalam
Combination Product · Drug
Lead sponsor
Rafa Laboratories
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Jul 23, 2026, 4:10 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

NCT05671653
View directory record Official record
Conditions
Obesity
Interventions
PF-07081532, Semaglutide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lazertinib (JNJ-73841937) in Healthy Participants

NCT05076877
View directory record Official record
Conditions
Healthy
Interventions
Lazertinib, Midazolam, Rosuvastatin, Metformin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers

NCT02204501
View directory record Official record
Conditions
Drug-Drug Interaction Healthy Volunteers
Interventions
Midazolam 5mg Syrup, Vapendavir 264 mg BID, Vapendavir 528 mg QD
Drug
Lead sponsor
Biota Scientific Management Pty Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Results available

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

NCT01937260
View directory record Official record
Conditions
Psoriasis
Interventions
Brodalumab
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Anaheim, California • Irvine, California • Ocala, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

NCT05395117
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5462, Midazolam, Rosuvastatin, Digoxin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional

To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients

NCT00258050
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Midazolam, Lapatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Lebanon, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

NCT05932277
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986419, Caffeine, Bupropion, Flurbiprofen, Omeprazole, Midazolam, Fexofenadine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam

NCT01925911
View directory record Official record
Conditions
Healthy
Interventions
IPI-145, Midazolam
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

NCT03363815
View directory record Official record
Conditions
Heathy Volunteer
Interventions
CC-90001, Omeprazole, Midazolam, Warfarin, Vitamin K, Rosuvastatin, Metformin, Digoxin, Nintedanib
Drug · Dietary Supplement
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 23, 2026, 4:10 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625
View directory record Official record
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Interventions
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects

NCT02505997
View directory record Official record
Conditions
VA Drug Interactions
Interventions
Midazolam, Delafloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

NCT02208882
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
BMS-986120, Placebo, Midazolam
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2015 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With a Potential Alzheimer's Disease Compound

NCT00726726
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2008 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects

NCT01757756
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
Pf-05175157, placebo, midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2012 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

NCT05438303
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

NCT04425902
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 200 mg, Caffeine 200 mg, Metoprolol 100 mg, Montelukast 10 mg, Flurbiprofen 100 mg, Omeprazole 40 mg, Midazolam 5 mg (2.5 mL), Digoxin 0.25 mg, Pravastatin 40 mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of BLU-808 in Healthy Adult Participants

NCT06948032
View directory record Official record
Conditions
Healthy Participants
Interventions
BLU-808, Placebo, Midazolam
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
19 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Isavuconazole and Midazolam

NCT01406171
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Midazolam, Healthy Volunteers
Interventions
Isavuconazole, Midazolam
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2011 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers

NCT03831971
View directory record Official record
Conditions
Opiod Use Disorder
Interventions
ANS-6637
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 23, 2026, 4:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

NCT02578277
View directory record Official record
Conditions
HIV Infections
Interventions
CYP and transporter probe substrates, BMS-955176, BMS-955176 plus CYP and transporter probe substrates
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Jul 23, 2026, 4:10 AM EDT